Loading
Life sciences · Journal article
Frontiers in Pharmacology · October 9, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Increasing evidence shows that cancer-associated fibroblasts (CAFs) contribute to tumor progression, create an immunosuppressive microenvironment, and promote resistance to immunotherapy. However, the CAF-related gene signature in pancreatic ductal adenocarcinoma (PDAC) remains largely unexplored. In our study, we constructed a nine-gene CAF-related signature and found that it strongly correlated with the prognosis of PDAC patients in different cohorts. Subsequently, we found that the CAF-related gene signature was associated with the genomic alteration landscape, immune infiltration landscape and responsiveness to immunotherapy. GJB2 had the highest coefficient in our CAF-related gene signature, thus we explored the role of GJB2 in the interactions between CAFs and PDAC cells. The results showed that conditioned medium (CM) derived from the GJB2 knockdown group could suppress the malignant phenotype of PANC1 and MIAPaCa2 cells. In summary, this CAF-related gene signature is useful for prognosis prediction and precision therapy of PDAC patients.